T

he little Australian biotech firm that once counted U.S. Health and Human Services Secretary Tom Price as a shareholder — a link that roiled his Senate confirmation hearing last winter — is facing closure, the company has told shareholders.

Innate Immunotherapeutics will probably shut down in the coming months, CEO Simon Wilkinson said at the company’s annual meeting Wednesday, The Australian, a news outlet, reported.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X